The gut microbiome as a target for regulatory T cell-based immunotherapy: induction of regulatory lymphocytes by oral administration of anti-LPS enriched colostrum alleviates immune mediated colitis

BMC Gastroenterology

Yaron Ilan¹  Lidya Zolotarov¹  Yoav Lichtenstein¹  Ami Ben Yaʼacov¹ 

[1] Gastroenterology and liver Unit, Department of Medicine, Hadassah Hebrew University Medical Center, Jerusalem, Israel

关键词: Crohn’s disease;    Inflammatory bowel disease;    Colostrum;    Regulatory T cells;    Microbiome;   

Others  :  1234291
DOI  :  10.1186/s12876-015-0388-x

 received in 2015-09-14, accepted in 2015-10-25,  发布年份 2015

【 摘 要 】

Background

Gut-derived bacterial endotoxin is an important cofactor in the pathogenesis of IBD. Regulatory T cells (Tregs) are essential for maintenance of peripheral tolerance and can prevent and alleviate IBD. To determine the immune modulatory effect of anti-LPS enriched hyperimmune colostrum, its ability to induce Tregs and alleviate immune mediated colitis.

Methods

Immune-mediated colitis was induced in mice by intra-colonic instillation of Trinitrobenzene Sulfonate (TNBS). Four groups of mice were orally administered with two dosages of IgG-enriched colostrum fractions. The fractions were harvested from cows immunized against LPS derived from intestinal Escherichia coli bacteria (Imm124E). Control mice received non-immunized colostrum or vehicle (PBS). Treatment was administered one day following sensitization and four additional days following the administration of TNBS. The following parameters in the mice were tracked: body weight, bowel histology, serum cytokine levels and regulatory T cells.

Results

Oral administration of Imm124E hyperimmune colostrum ameliorated immune-mediated colitis. Significant amelioration of weight reduction was noted in treated mice. Oral administration of Imm124E improved bowel histology. Both the extent of the disease, inflammation score, and colitis damage and regeneration scores decreased in Imm-124E treated animals. These effects were associated with an increase in serum IL10 anti inflammatory cytokine levels, and an increase in CD4 + CD25+ and CD4 + Foxp3+ Tregs.

Conclusions

Oral administration of Imm124E promoted Tregs and alleviated bowel inflammation in immune mediated colitis. The present data suggests that the microbiome may serve as a target for Tregs-based immunotherapy.

【 授权许可】

   
2015 Yaʼacov et al.

【 图 表 】

Fig. 1.

Fig. 2.

Fig. 3.

Fig. 4.

【 参考文献 】

• [1]Robles Alonso V, Guarner F: Linking the gut microbiota to human health. Br J Nutr 2013, 109(Suppl 2):S21-6.
• [2]Hammer HF: Gut microbiota and inflammatory bowel disease. Dig Dis 2011, 29:550-3.
• [3]Loh G, Blaut M: Role of commensal gut bacteria in inflammatory bowel diseases. Gut Microbes 2012, 3:544-55.
• [4]Vignali DA, Collison LW, Workman CJ: How regulatory T cells work. Nat Rev Immunol 2008, 8:523-32.
• [5]Faria AM, Weiner HL: Oral tolerance: therapeutic implications for autoimmune diseases. Clin Dev Immunol 2006, 13:143-57.
• [6]Ochi H, Abraham M, Ishikawa H, Frenkel D, Yang K, Basso AS, et al.: Oral CD3-specific antibody suppresses autoimmune encephalomyelitis by inducing CD4+ CD25- LAP+ T cells. Nat Med. 2006, 12:627-35.
• [7]Mizrahi M, Ben Ya'acov A, Ilan Y: Gastric stimulation for weight loss. World J Gastroenterol 2012, 18:2309-19.
• [8]Ilan Y, Maron R, Tukpah AM, Maioli TU, Murugaiyan G, Yang K, et al.: Induction of regulatory T cells decreases adipose inflammation and alleviates insulin resistance in ob/ob mice. Proc Natl Acad Sci U S A (PNAS) 2010, 107:9765-70.
• [9]Forster K, Goethel A, Chan CW, Zanello G, Streutker C, Croitoru K: An oral CD3-specific antibody suppresses T-cell-induced colitis and alters cytokine responses to T-cell activation in mice. Gastroenterology. 2012, 143:1298-307.
• [10]Mero A, Miikkulainen H, Riski J, Pakkanen R, Aalto J, Takala T: Effects of bovine colostrum supplementation on serum IGF-I, IgG, hormone, and saliva IgA during training. J Appl Physiol. 1997, 83:1144-51.
• [11]Severin S, Wenshui X: Milk biologically active components as nutraceuticals: review. Crit Rev Food Sci Nutr 2005, 45:645-56.
• [12]Buescher ES, McWilliams-Koeppen P: Soluble tumor necrosis factor-alpha (TNF-alpha) receptors in human colostrum and milk bind to TNF-alpha and neutralize TNF-alpha bioactivity. Pediatr Res 1998, 44:37-42.
• [13]Garofalo RP, Goldman AS: Cytokines, chemokines, and colony-stimulating factors in human milk: the 1997 update. Biol Neonate 1998, 74:134-42.
• [14]Adar T, Ben Ya'acov A, Lalazar G, Lichtenstein Y, Nahman D, Mizrahi M, et al.: Oral administration of immunoglobulin G-enhanced colostrum alleviates insulin resistance and liver injury and is associated with alterations in natural killer T cells. Clin Exp Immunol. 2012, 167:252-60.
• [15]Mizrahi M, Shabat Y, Ben Ya'acov A, Lalazar G, Adar T, Wong V, et al.: Alleviation of insulin resistance and liver damage by oral administration of Imm124-E is mediated by increased Tregs and associated with increased serum GLP-1 and adiponectin: results of a phase I/II clinical trial in NASH. J Inflamm Res. 2012, 5:141-50.
• [16]Dieleman LA, Ridwan BU, Tennyson GS, Beagley KW, Bucy RP, Elson CO: Dextran sulfate sodium-induced colitis occurs in severe combined immunodeficient mice. Gastroenterology. 1994, 107:1643-52.
• [17]Diehl GE, Longman RS, Zhang JX, Breart B, Galan C, Cuesta A, et al.: Microbiota restricts trafficking of bacteria to mesenteric lymph nodes by CX(3)CR1(hi) cells. Nature. 2013, 494:116-20.
• [18]Kurzweil V, Tarangelo A, Oliver PM: Gastrointestinal microbiota do not significantly contribute to T cell activation or GI inflammation in Ndfip1-cKO mice. PLoS One 2012, 7:e34478.
• [19]Hand TW, Dos Santos LM, Bouladoux N, Molloy MJ, Pagan AJ, Pepper M: Acute gastrointestinal infection induces long-lived microbiota-specific T cell responses. Science. 2012, 337:1553-6.
• [20]Zimmermann K, Haas A, Oxenius A: Systemic antibody responses to gut microbes in health and disease. Gut Microbes 2012, 3:42-7.
• [21]Macutkiewicz C, Carlson G, Clark E, Dobrindt U, Roberts I, Warhurst G: Characterisation of Escherichia coli strains involved in transcytosis across gut epithelial cells exposed to metabolic and inflammatory stress. Microbes Infect. 2008, 10:424-31.
• [22]Pearson JS, Giogha C, Ong SY, Kennedy CL, Kelly M, Robinson KS, et al.: A type III effector antagonizes death receptor signalling during bacterial gut infection. Nature. 2013, 501:247-51.
• [23]Miele L, Valenza V, La Torre G, Montalto M, Cammarota G, Ricci R, et al.: Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology. 2009, 49:1877-87.
• [24]Balzan S, de Almeida QC, de Cleva R, Zilberstein B, Cecconello I: Bacterial translocation: overview of mechanisms and clinical impact. J Gastroenterol Hepatol. 2007, 22:464-71.
• [25]Walzer N, Buchman AL: Development of Crohn’s disease in patients with intestinal failure: a role for bacteria? J Clin Gastroenterol 2010, 44:361-3.
• [26]Lakatos PL, Kiss LS, Palatka K, Altorjay I, Antal-Szalmas P, Palyu E, et al.: Serum lipopolysaccharide-binding protein and soluble CD14 are markers of disease activity in patients with Crohn’s disease. Inflamm Bowel Dis. 2011, 17:767-77.
• [27]Himmel ME, Yao Y, Orban PC, Steiner TS, Levings MK: Regulatory T-cell therapy for inflammatory bowel disease: more questions than answers. Immunology. 2012, 136:115-22.
• [28]Shevach EM: From vanilla to 28 flavors: multiple varieties of T regulatory cells. Immunity 2006, 25:195-201.
• [29]de St Groth BF: Regulatory T-cell abnormalities and the global epidemic of immuno-inflammatory disease. Immunol Cell Biol 2012, 90:256-9.
• [30]Kelly D, Mulder IE: Microbiome and immunological interactions. Nutr Rev 2012, 70(Suppl 1):S18-30.
• [31]Schmitt EG, Haribhai D, Williams JB, Aggarwal P, Jia S, Charbonnier LM, et al.: IL-10 produced by induced regulatory T cells (iTregs) controls colitis and pathogenic ex-iTregs during immunotherapy. J Immunol. 2012, 189:5638-48.
• [32]Admyre C, Johansson SM, Qazi KR, Filen JJ, Lahesmaa R, Norman M, et al.: Exosomes with immune modulatory features are present in human breast milk. J Immunol. 2007, 179:1969-78.
• [33]Oppenheim JJ, Yang D: Alarmins: chemotactic activators of immune responses. Curr Opin Immunol 2005, 17:359-65.
• [34]Martin MJ, Martin-Sosa S, Hueso P: Bovine milk gangliosides: changes in ceramide moiety with stage of lactation. Lipids 2001, 36:291-8.
• [35]Sala-Vila A, Castellote AI, Rodriguez-Palmero M, Campoy C, Lopez-Sabater MC: Lipid composition in human breast milk from Granada (Spain): changes during lactation. Nutrition. 2005, 21:467-73.
• [36]Oppenheim JJ, Tewary P, de la Rosa G, Yang D: Alarmins initiate host defense. Adv Exp Med Biol. 2007, 601:185-94.
• [37]Homann D, Holz A, Bot A, Coon B, Wolfe T, Petersen J, et al.: Autoreactive CD4+ T cells protect from autoimmune diabetes via bystander suppression using the IL-4/Stat6 pathway. Immunity. 1999, 11:463-72.
• [38]Ilan Y: A fourth dimension in decision making in hepatology. Hepatol Res 2010, 40:1143-54.
• [39]Ilan Y, Maron R, Tukpah AM, Maioli TU, Murugaiyan G, Yang K, et al.: Induction of regulatory T cells decreases adipose inflammation and alleviates insulin resistance in ob/ob mice. Proc Natl Acad Sci U S A. 2010, 107:9765-70.
• [40]Ilan Y, Zigmond E, Lalazar G, Dembinsky A, Ben Ya'acov A, Hemed N, et al.: Oral administration of OKT3 monoclonal antibody to human subjects induces a dose-dependent immunologic effect in T cells and dendritic cells. J Clin Immunol. 2010, 30:167-77.